Other News To Note
• ConfometRx, of Palo Alto, Calif., signed a research agreement with UCB SA, of Brussels, Belgium, to pursue the discovery of medicines addressing unmet medical needs in neuroscience. Under the two-year, multi-target agreement, the companies will leverage structural biology to gain insight into G-protein coupled receptor modulation, with an eye toward the design of differentiated drugs.
